Abstract: The disclosure is directed to method of inhibiting cancer cell growth by contacting cancer cells with a dose of an anti-cancer agent that is divided equally between a nanoparticle carrier encapsulating the anti-cancer agent and antibody carrier that binds to a cancer-specific receptor and is conjugated to the same anti-cancer agent.

Abstract: Lipid-based nanocarriers (liposomes) loaded with a chemotherapeutic agent and exhibiting interstitial drug release and intratumoral adhesion are disclosed. The lipid-based nanocarriers disclosed herein include an ‘adsorptive/adhesive switch’ on the nanocarriers surface with the aim to increase the tumor residence times of the drug delivery nanocarriers and to slow down their tumor clearing kinetics. The switch is designed to promote nanoparticle adsorption on cancer cells and/or the extracellular matrix (ECM) while keeping their internalization by cells to a minimum. This approach of drug delivery is key for interstitial release of highly-diffusive forms of therapeutics.

Abstract: Using liposomes to deliver bioactive agents to cancer or tumor cells and compositions of specific lipids that form liposomes to deliver a biologically active agent. A liposome composition for delivering of a biologically active agent, comprising liposomes comprising at a least first rigid lipid and a second rigid lipid each having a head group and a hydrophobic tail; a polyethyleneglycol-linked lipid having a side chain matching at least a portion of the first or the second lipid; and an entrapped biologically active agent. The first lipid can be a zwitterionic lipid and the second lipid can have a titratable head group. The composition can be adapted to release the entrapped at a certain pH.

Abstract: A liposome composition for delivering of a biologically active agent having at a least first rigid lipid and a second rigid lipid each having a head group and a hydrophobic tail; a polyethyleneglycol-linked lipid having a side chain matching at least a portion of the first or the second lipid; and an entrapped biologically active agent. The first lipid can be a zwitterionic lipid and the second lipid can have a titratable head group. The composition can be adapted to release the entrapped at a certain pH.

Abstract: The present invention provides targeted delivery of alpha particle-emitting radionuclides and their alpha-emitting progeny using liposomal encapsulation to reduce the loss of daughter radionuclides from the targeting vehicle and, therefore, from the tumor site. Also provided are encapsulated alpha particle-emitting radionuclides.

Abstract: The present invention provides targeted delivery of alpha particle-emitting radionuclides and their alpha-emitting progeny using liposomal encapsulation to prevent the loss of daughter radionuclides from the targeting vehicle and, therefore, from the tumor site.